Will OncuraKit add more miRNA markers in the future?

Yenos Analytical is actively researching additional miRNA markers that could expand the panel. Potential additions include miR-155 (associated with blood cancers and inflammatory cancers), miR-126 (associated with lung and gastric cancer), and other broadly validated oncomiRs. Adding markers could increase sensitivity for specific cancer types or enable detection of cancer types not currently covered. However, each new marker must be validated through the same rigorous process (clinical sample testing, HL threshold establishment, bracketing protocol validation) before being added to the clinical panel. The current three-marker panel was selected as the strongest, most validated starting point. Expansion of the panel is a future development direction as additional validation data is accumulated.